- SyVento Biotech has launched its new mRNA manufacturing facility in Poland, featuring an advanced FlexFactory system.
- The facility is the first mRNA manufacturing site in Poland and the first in Europe equipped with the Historian automation system.
SyVento Biotech, a contract development and manufacturing organisation (CDMO), has announced the opening of its new mRNA manufacturing facility in Poland. This state-of-the-art site, spanning over 7,000 m², includes lab and production areas, offices, and shared spaces. It marks a significant milestone in SyVento’s expansion and positions the company as a leader in the European mRNA manufacturing space.
The new facility is equipped with Cytiva’s FlexFactory platform, which integrates multiple technologies for end-to-end mRNA production. This includes key components such as encapsulation steps and single-use consumables for filling processes. Notably, the facility is the first in Poland and the first in Europe to incorporate Cytiva’s Historian automation system. This system centralises, aggregates, and archives manufacturing data, ensuring data integrity and compliance while improving manufacturing efficiency.
Dominik Lipka, Chief Technology Officer at SyVento Biotech, highlighted that the new facility allows the company to offer a comprehensive service for clients. “We offer a one-stop-shop for our partners and clients, so they can produce new mRNA therapies from lab scale to commercial production,” Lipka said. The facility will support the development of mRNA therapies for COVID-19, cancer, and other conditions, helping to make these treatments available to patients more efficiently.
Ludovic Brellier, President of Hardware Solutions at Cytiva, echoed the importance of the partnership. “Cytiva and SyVento Biotech are wholly committed to fostering innovation and growth in the biotechnology sector,” he stated, underlining the shared goal of improving access to cutting-edge therapies.
Overview of outsourcing trends 
